Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)

Jay S. Cooper, Matthew D. Guo, Arnold Herskovic, John S. Macdonald, James A. Martenson, Muhyi Al-Sarraf, Roger Byhardt, Anthony H. Russell, Jonathan J. Beitler, Sharon Spencer, Sucha O. Asbell, Mary V. Graham, Lawrence L. Leichman

Research output: Contribution to journalArticle

1324 Citations (Scopus)

Abstract

Context: Carcinoma of the esophagus traditionally has been treated by surgery or radiation therapy (RT), but 5-year overall survival rates have been only 5% to 10%. We previously reported results of a study conducted from January 1986 to April 1990 of combined chemotherapy and RT vs RT alone when an interim analysis revealed significant benefit for combined therapy. Objective: To report the long-term outcomes of a previously reported trial designed to determine if adding chemotherapy during RT improves the survival rate of patients with esophageal carcinoma. Design: Randomized controlled trial conducted 1985 to 1990 with follow-up of at least 5 years, followed by a prospective cohort study conducted between May 1990 and April 1991. Setting: Multi-institution participation, ranging from tertiary academic referral centers to general community practices. Patients. Patients had squamous cell or adenocarcinoma of the esophagus, T1-3 N0-1 M0, adequate renal and bone marrow reserve, and a Karnofsky score of at least 50. Interventions: Combined modality therapy (n = 134): 50 Gy in 25 fractions over 5 weeks, plus cisplatin intravenously on the first day of weeks 1, 5, 8, and 11, and fluorouracil, 1 g/m2 per day by continuous infusion on the first 4 days of weeks 1, 5, 8, and 11. In the randomized study, combined therapy was compared with RT only (n = 62): 64 Gy in 32 fractions over 6.4 weeks. Main Outcome Measures: Overall survival, patterns of failure, and toxic effects. Results: Combined therapy significantly increased overall survival corn pared with RT alone. In the randomized part of the trial, at 5 years of follow-up the overall survival for combined therapy was 26% (95% confidence interval [CI], 15%-37%) compared with 0% following RT. In the succeeding nonrandomized part, combined therapy produced a 5-year overall survival of 14% (95% CI, 6%-23%). Persistence of disease (despite therapy) was the most common mode of treatment failure; however, it was less common in the groups receiving combined therapy (34/130 [26%]) than in the group treated with RT only (23/62 [37%]). Severe acute toxic effects also were greater in the combined therapy groups. There were no significant differences in severe late toxic effects between the groups. However, chemotherapy could be administered as planned in only 89 (68%) of 130 patients (10% had life-threatening toxic effects with combined therapy vs 2% in the RT only group). Conclusion: Combined therapy increases the survival of patients who have squamous cell or adenocarcinoma of the esophagus. T1-3 N0-1 M0, compared with RT alone.

Original languageEnglish (US)
Pages (from-to)1623-1627
Number of pages5
JournalJournal of the American Medical Association
Volume281
Issue number17
DOIs
StatePublished - May 5 1999
Externally publishedYes

Fingerprint

Chemoradiotherapy
Esophageal Neoplasms
Radiotherapy
Poisons
Therapeutics
Survival
Drug Therapy
Survival Rate
Epithelial Cells
Confidence Intervals
Carcinoma
Combined Modality Therapy
Group Psychotherapy
Treatment Failure
Tertiary Care Centers
Fluorouracil
General Practice
Cisplatin
Esophagus
Zea mays

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cooper, J. S., Guo, M. D., Herskovic, A., Macdonald, J. S., Martenson, J. A., Al-Sarraf, M., ... Leichman, L. L. (1999). Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Journal of the American Medical Association, 281(17), 1623-1627. https://doi.org/10.1001/jama.281.17.1623

Chemoradiotherapy of locally advanced esophageal cancer : Long-term follow-up of a prospective randomized trial (RTOG 85-01). / Cooper, Jay S.; Guo, Matthew D.; Herskovic, Arnold; Macdonald, John S.; Martenson, James A.; Al-Sarraf, Muhyi; Byhardt, Roger; Russell, Anthony H.; Beitler, Jonathan J.; Spencer, Sharon; Asbell, Sucha O.; Graham, Mary V.; Leichman, Lawrence L.

In: Journal of the American Medical Association, Vol. 281, No. 17, 05.05.1999, p. 1623-1627.

Research output: Contribution to journalArticle

Cooper, JS, Guo, MD, Herskovic, A, Macdonald, JS, Martenson, JA, Al-Sarraf, M, Byhardt, R, Russell, AH, Beitler, JJ, Spencer, S, Asbell, SO, Graham, MV & Leichman, LL 1999, 'Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)', Journal of the American Medical Association, vol. 281, no. 17, pp. 1623-1627. https://doi.org/10.1001/jama.281.17.1623
Cooper, Jay S. ; Guo, Matthew D. ; Herskovic, Arnold ; Macdonald, John S. ; Martenson, James A. ; Al-Sarraf, Muhyi ; Byhardt, Roger ; Russell, Anthony H. ; Beitler, Jonathan J. ; Spencer, Sharon ; Asbell, Sucha O. ; Graham, Mary V. ; Leichman, Lawrence L. / Chemoradiotherapy of locally advanced esophageal cancer : Long-term follow-up of a prospective randomized trial (RTOG 85-01). In: Journal of the American Medical Association. 1999 ; Vol. 281, No. 17. pp. 1623-1627.
@article{90ca9ad4ddd84c7181da5641225f8bf7,
title = "Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)",
abstract = "Context: Carcinoma of the esophagus traditionally has been treated by surgery or radiation therapy (RT), but 5-year overall survival rates have been only 5{\%} to 10{\%}. We previously reported results of a study conducted from January 1986 to April 1990 of combined chemotherapy and RT vs RT alone when an interim analysis revealed significant benefit for combined therapy. Objective: To report the long-term outcomes of a previously reported trial designed to determine if adding chemotherapy during RT improves the survival rate of patients with esophageal carcinoma. Design: Randomized controlled trial conducted 1985 to 1990 with follow-up of at least 5 years, followed by a prospective cohort study conducted between May 1990 and April 1991. Setting: Multi-institution participation, ranging from tertiary academic referral centers to general community practices. Patients. Patients had squamous cell or adenocarcinoma of the esophagus, T1-3 N0-1 M0, adequate renal and bone marrow reserve, and a Karnofsky score of at least 50. Interventions: Combined modality therapy (n = 134): 50 Gy in 25 fractions over 5 weeks, plus cisplatin intravenously on the first day of weeks 1, 5, 8, and 11, and fluorouracil, 1 g/m2 per day by continuous infusion on the first 4 days of weeks 1, 5, 8, and 11. In the randomized study, combined therapy was compared with RT only (n = 62): 64 Gy in 32 fractions over 6.4 weeks. Main Outcome Measures: Overall survival, patterns of failure, and toxic effects. Results: Combined therapy significantly increased overall survival corn pared with RT alone. In the randomized part of the trial, at 5 years of follow-up the overall survival for combined therapy was 26{\%} (95{\%} confidence interval [CI], 15{\%}-37{\%}) compared with 0{\%} following RT. In the succeeding nonrandomized part, combined therapy produced a 5-year overall survival of 14{\%} (95{\%} CI, 6{\%}-23{\%}). Persistence of disease (despite therapy) was the most common mode of treatment failure; however, it was less common in the groups receiving combined therapy (34/130 [26{\%}]) than in the group treated with RT only (23/62 [37{\%}]). Severe acute toxic effects also were greater in the combined therapy groups. There were no significant differences in severe late toxic effects between the groups. However, chemotherapy could be administered as planned in only 89 (68{\%}) of 130 patients (10{\%} had life-threatening toxic effects with combined therapy vs 2{\%} in the RT only group). Conclusion: Combined therapy increases the survival of patients who have squamous cell or adenocarcinoma of the esophagus. T1-3 N0-1 M0, compared with RT alone.",
author = "Cooper, {Jay S.} and Guo, {Matthew D.} and Arnold Herskovic and Macdonald, {John S.} and Martenson, {James A.} and Muhyi Al-Sarraf and Roger Byhardt and Russell, {Anthony H.} and Beitler, {Jonathan J.} and Sharon Spencer and Asbell, {Sucha O.} and Graham, {Mary V.} and Leichman, {Lawrence L.}",
year = "1999",
month = "5",
day = "5",
doi = "10.1001/jama.281.17.1623",
language = "English (US)",
volume = "281",
pages = "1623--1627",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "17",

}

TY - JOUR

T1 - Chemoradiotherapy of locally advanced esophageal cancer

T2 - Long-term follow-up of a prospective randomized trial (RTOG 85-01)

AU - Cooper, Jay S.

AU - Guo, Matthew D.

AU - Herskovic, Arnold

AU - Macdonald, John S.

AU - Martenson, James A.

AU - Al-Sarraf, Muhyi

AU - Byhardt, Roger

AU - Russell, Anthony H.

AU - Beitler, Jonathan J.

AU - Spencer, Sharon

AU - Asbell, Sucha O.

AU - Graham, Mary V.

AU - Leichman, Lawrence L.

PY - 1999/5/5

Y1 - 1999/5/5

N2 - Context: Carcinoma of the esophagus traditionally has been treated by surgery or radiation therapy (RT), but 5-year overall survival rates have been only 5% to 10%. We previously reported results of a study conducted from January 1986 to April 1990 of combined chemotherapy and RT vs RT alone when an interim analysis revealed significant benefit for combined therapy. Objective: To report the long-term outcomes of a previously reported trial designed to determine if adding chemotherapy during RT improves the survival rate of patients with esophageal carcinoma. Design: Randomized controlled trial conducted 1985 to 1990 with follow-up of at least 5 years, followed by a prospective cohort study conducted between May 1990 and April 1991. Setting: Multi-institution participation, ranging from tertiary academic referral centers to general community practices. Patients. Patients had squamous cell or adenocarcinoma of the esophagus, T1-3 N0-1 M0, adequate renal and bone marrow reserve, and a Karnofsky score of at least 50. Interventions: Combined modality therapy (n = 134): 50 Gy in 25 fractions over 5 weeks, plus cisplatin intravenously on the first day of weeks 1, 5, 8, and 11, and fluorouracil, 1 g/m2 per day by continuous infusion on the first 4 days of weeks 1, 5, 8, and 11. In the randomized study, combined therapy was compared with RT only (n = 62): 64 Gy in 32 fractions over 6.4 weeks. Main Outcome Measures: Overall survival, patterns of failure, and toxic effects. Results: Combined therapy significantly increased overall survival corn pared with RT alone. In the randomized part of the trial, at 5 years of follow-up the overall survival for combined therapy was 26% (95% confidence interval [CI], 15%-37%) compared with 0% following RT. In the succeeding nonrandomized part, combined therapy produced a 5-year overall survival of 14% (95% CI, 6%-23%). Persistence of disease (despite therapy) was the most common mode of treatment failure; however, it was less common in the groups receiving combined therapy (34/130 [26%]) than in the group treated with RT only (23/62 [37%]). Severe acute toxic effects also were greater in the combined therapy groups. There were no significant differences in severe late toxic effects between the groups. However, chemotherapy could be administered as planned in only 89 (68%) of 130 patients (10% had life-threatening toxic effects with combined therapy vs 2% in the RT only group). Conclusion: Combined therapy increases the survival of patients who have squamous cell or adenocarcinoma of the esophagus. T1-3 N0-1 M0, compared with RT alone.

AB - Context: Carcinoma of the esophagus traditionally has been treated by surgery or radiation therapy (RT), but 5-year overall survival rates have been only 5% to 10%. We previously reported results of a study conducted from January 1986 to April 1990 of combined chemotherapy and RT vs RT alone when an interim analysis revealed significant benefit for combined therapy. Objective: To report the long-term outcomes of a previously reported trial designed to determine if adding chemotherapy during RT improves the survival rate of patients with esophageal carcinoma. Design: Randomized controlled trial conducted 1985 to 1990 with follow-up of at least 5 years, followed by a prospective cohort study conducted between May 1990 and April 1991. Setting: Multi-institution participation, ranging from tertiary academic referral centers to general community practices. Patients. Patients had squamous cell or adenocarcinoma of the esophagus, T1-3 N0-1 M0, adequate renal and bone marrow reserve, and a Karnofsky score of at least 50. Interventions: Combined modality therapy (n = 134): 50 Gy in 25 fractions over 5 weeks, plus cisplatin intravenously on the first day of weeks 1, 5, 8, and 11, and fluorouracil, 1 g/m2 per day by continuous infusion on the first 4 days of weeks 1, 5, 8, and 11. In the randomized study, combined therapy was compared with RT only (n = 62): 64 Gy in 32 fractions over 6.4 weeks. Main Outcome Measures: Overall survival, patterns of failure, and toxic effects. Results: Combined therapy significantly increased overall survival corn pared with RT alone. In the randomized part of the trial, at 5 years of follow-up the overall survival for combined therapy was 26% (95% confidence interval [CI], 15%-37%) compared with 0% following RT. In the succeeding nonrandomized part, combined therapy produced a 5-year overall survival of 14% (95% CI, 6%-23%). Persistence of disease (despite therapy) was the most common mode of treatment failure; however, it was less common in the groups receiving combined therapy (34/130 [26%]) than in the group treated with RT only (23/62 [37%]). Severe acute toxic effects also were greater in the combined therapy groups. There were no significant differences in severe late toxic effects between the groups. However, chemotherapy could be administered as planned in only 89 (68%) of 130 patients (10% had life-threatening toxic effects with combined therapy vs 2% in the RT only group). Conclusion: Combined therapy increases the survival of patients who have squamous cell or adenocarcinoma of the esophagus. T1-3 N0-1 M0, compared with RT alone.

UR - http://www.scopus.com/inward/record.url?scp=0033526355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033526355&partnerID=8YFLogxK

U2 - 10.1001/jama.281.17.1623

DO - 10.1001/jama.281.17.1623

M3 - Article

C2 - 10235156

AN - SCOPUS:0033526355

VL - 281

SP - 1623

EP - 1627

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 17

ER -